CHLITINA-KY (4137) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 麗豐-KY

CHLITINA-KY (4137) reported revenue of NT$370 million for Oct 2026, +3.9% year on year and -22.7% from the previous month. Revenue for Jan–Oct 2026 was NT$3.36 billion (+7.2% year on year).

In Oct 2026, it ranked No. 25 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$337.7 million24/10Nov 2024 NT$339.9 millionDec 2024 NT$349.7 millionJan 2025 NT$174.4 millionFeb 2025 NT$292.1 million25/02Mar 2025 NT$331.4 millionApr 2025 NT$333.9 millionMay 2025 NT$333.9 millionJun 2025 NT$285 million25/06Jul 2025 NT$310 millionAug 2025 NT$322.6 millionSep 2025 NT$392.4 millionOct 2025 NT$356.2 million25/10Nov 2025 NT$358.5 millionDec 2025 NT$387.9 millionJan 2026 NT$378.6 millionFeb 2026 NT$195.9 million26/02Mar 2026 NT$343.5 millionApr 2026 NT$348.8 millionMay 2026 NT$285.2 millionJun 2026 NT$349.4 million26/06Jul 2026 NT$318.6 millionAug 2026 NT$288 millionSep 2026 NT$478.8 millionOct 2026 NT$370 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$370 million+3.9%-22.7%
Sep 2026NT$478.8 million+22.0%+66.2%
Aug 2026NT$288 million-10.7%-9.6%
Jul 2026NT$318.6 million+2.8%-8.8%
Jun 2026NT$349.4 million+22.6%+22.5%
May 2026NT$285.2 million-14.6%-18.2%
Apr 2026NT$348.8 million+4.5%+1.5%
Mar 2026NT$343.5 million+3.7%+75.3%
Feb 2026NT$195.9 million-32.9%-48.3%
Jan 2026NT$378.6 million+117.2%-2.4%
Dec 2025NT$387.9 million+10.9%+8.2%
Nov 2025NT$358.5 million+5.5%+0.7%
Oct 2025NT$356.2 million+5.5%-9.2%
Sep 2025NT$392.4 million+4.8%+21.6%
Aug 2025NT$322.6 million-2.1%+4.1%
Jul 2025NT$310 million-2.8%+8.8%
Jun 2025NT$285 million-5.9%-14.7%
May 2025NT$333.9 million-10.9%+0.0%
Apr 2025NT$333.9 million-2.0%+0.8%
Mar 2025NT$331.4 million-12.6%+13.5%
Feb 2025NT$292.1 million+17.4%+67.5%
Jan 2025NT$174.4 million-52.9%-50.1%
Dec 2024NT$349.7 million-11.0%+2.9%
Nov 2024NT$339.9 million-19.7%+0.6%
Oct 2024NT$337.7 million-18.2%-9.8%

Jan–Oct 2026 cumulative: NT$3.36 billion (+7.2% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: CHLITINA-KY vs PEC / CHLITINA-KY vs Lotus Pharm / CHLITINA-KY vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16